- Conditions
- Breast Cancer
- Interventions
- Eribulin Mesylate, Ixabepilone
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 50
- States / cities
- Sedona, Arizona • Hawthorne, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 5:34 PM EDT